Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Notes Payables (2016 - 2024)

Historic Notes Payables for Aytu Biopharma (AYTU) over the last 7 years, with Q4 2024 value amounting to $4.0 million.

  • Aytu Biopharma's Notes Payables rose 29103.31% to $4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.0 million, marking a year-over-year increase of 29103.31%. This contributed to the annual value of $2.4 million for FY2024, which is 5323.1% up from last year.
  • According to the latest figures from Q4 2024, Aytu Biopharma's Notes Payables is $4.0 million, which was up 29103.31% from $4.3 million recorded in Q3 2024.
  • In the past 5 years, Aytu Biopharma's Notes Payables ranged from a high of $10.4 million in Q1 2023 and a low of $41318.0 during Q4 2020
  • Over the past 4 years, Aytu Biopharma's median Notes Payables value was $2.0 million (recorded in 2024), while the average stood at $3.2 million.
  • Its Notes Payables has fluctuated over the past 5 years, first crashed by 8618.93% in 2023, then soared by 29103.31% in 2024.
  • Over the past 4 years, Aytu Biopharma's Notes Payables (Quarter) stood at $41318.0 in 2020, then surged by 17880.06% to $7.4 million in 2022, then tumbled by 86.19% to $1.0 million in 2023, then skyrocketed by 291.03% to $4.0 million in 2024.
  • Its last three reported values are $4.0 million in Q4 2024, $4.3 million for Q3 2024, and $2.4 million during Q2 2024.